{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:20:54Z","timestamp":1791980454893,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:00:00Z","timestamp":1555632000000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["N01 AI 30065"],"award-info":[{"award-number":["N01 AI 30065"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["HHSN272201000401"],"award-info":[{"award-number":["HHSN272201000401"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["HHSN27200009"],"award-info":[{"award-number":["HHSN27200009"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIAID T32","award":["AI 07536"],"award-info":[{"award-number":["AI 07536"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.antiviral.2018.04.012","type":"journal-article","created":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T11:46:10Z","timestamp":1523706370000},"page":"104-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Spectrum of activity testing for therapeutics against all four dengue virus serotypes in AG129 mouse models: Proof-of-concept studies with the adenosine nucleoside inhibitor NITD-008"],"prefix":"10.1016","volume":"154","author":[{"given":"Gregg N.","family":"Milligan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellodee","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Zavala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Pyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1262-2101","authenticated-orcid":false,"given":"Vanessa V.","family":"Sarathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.T.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Bourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7446","key":"10.1016\/j.antiviral.2018.04.012_bib1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.04.012_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.antiviral.2015.08.013","article-title":"Animal models for studying dengue pathogenesis and therapy","volume":"123","author":"Chan","year":"2015","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2018.04.012_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2010.11.002","article-title":"Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo","volume":"89","author":"Chang","year":"2011","journal-title":"Antivir. Res."},{"issue":"30","key":"10.1016\/j.antiviral.2018.04.012_bib4","first-page":"349","article-title":"Dengue vaccine: WHO position paper - july 2016","volume":"91","year":"2016","journal-title":"Wkly. Epidemiol. Rec."},{"key":"10.1016\/j.antiviral.2018.04.012_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.antiviral.2014.08.004","article-title":"Modulation of inflammation and pathology during dengue virus infection by p38 MAPK inhibitor SB203580","volume":"110C","author":"Fu","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.012_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2014.08.087","article-title":"Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice","author":"Fuchs","year":"2014","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.antiviral.2018.04.012_bib7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.antiviral.2018.04.012_bib8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/JVI.73.1.783-786.1999","article-title":"New mouse model for dengue virus vaccine testing","volume":"73","author":"Johnson","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.04.012_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2016.06.002","article-title":"Towards antiviral therapies for treating dengue virus infections","volume":"30","author":"Kaptein","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.04.012_bib10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.antiviral.2013.09.013","article-title":"Ten years of dengue drug discovery: progress and prospects","volume":"100","author":"Lim","year":"2013","journal-title":"Antivir. Res."},{"issue":"5","key":"10.1016\/j.antiviral.2018.04.012_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125476","article-title":"A dengue virus type 4 model of disseminated lethal infection in AG129 mice","volume":"10","author":"Milligan","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.antiviral.2018.04.012_bib12","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1099\/jgv.0.000923","article-title":"A lethal model of disseminated dengue virus type 1 infection in AG129 mice","volume":"98","author":"Milligan","year":"2017","journal-title":"J. Gen. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2018.04.012_bib13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4269\/ajtmh.1983.32.577","article-title":"RNA fingerprinting as a method for distinguishing dengue 1 virus strains","volume":"32","author":"Repik","year":"1983","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"50","key":"10.1016\/j.antiviral.2018.04.012_bib14","doi-asserted-by":"crossref","first-page":"7051","DOI":"10.1016\/j.vaccine.2015.09.112","article-title":"Mouse models of dengue virus infection for vaccine testing","volume":"33","author":"Sarathy","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.antiviral.2018.04.012_bib15","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1128\/JVI.01320-14","article-title":"A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease","volume":"89","author":"Sarathy","year":"2015","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.antiviral.2018.04.012_bib16","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1099\/jgv.0.000246","article-title":"Characterization of lethal dengue virus type 4 (DENV-4) TVP-376 infection in mice lacking both IFN-alpha\/beta and IFN-gamma receptors (AG129) and comparison with the DENV-2 AG129 mouse model","volume":"96","author":"Sarathy","year":"2015","journal-title":"J. Gen. Virol."},{"issue":"20","key":"10.1016\/j.antiviral.2018.04.012_bib17","doi-asserted-by":"crossref","first-page":"10208","DOI":"10.1128\/JVI.00062-06","article-title":"Murine model for dengue virus-induced lethal disease with increased vascular permeability","volume":"80","author":"Shresta","year":"2006","journal-title":"J. Virol."},{"issue":"15","key":"10.1016\/j.antiviral.2018.04.012_bib18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMra1110265","article-title":"Dengue","volume":"366","author":"Simmons","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"50","key":"10.1016\/j.antiviral.2018.04.012_bib19","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1016\/j.vaccine.2015.09.103","article-title":"Recent advances in dengue pathogenesis and clinical management","volume":"33","author":"Simmons","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.antiviral.2018.04.012_bib20","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1371\/journal.pntd.0000672","article-title":"A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice","volume":"4","author":"Tan","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2018.04.012_bib21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.antiviral.2018.04.012_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2012.07.008","article-title":"Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial","volume":"96","author":"Watanabe","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.04.012_bib23","series-title":"Dengue: Guidelines for Diagnosis, Treatment, Prevention, and Control. New Ed","first-page":"147","author":"WHO","year":"2009"},{"issue":"48","key":"10.1016\/j.antiviral.2018.04.012_bib24","doi-asserted-by":"crossref","first-page":"20435","DOI":"10.1073\/pnas.0907010106","article-title":"An adenosine nucleoside inhibitor of dengue virus","volume":"106","author":"Yin","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.antiviral.2018.04.012_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.chom.2010.01.004","article-title":"Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease","volume":"7","author":"Zellweger","year":"2010","journal-title":"Cell Host Microbe"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217307453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217307453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:28:36Z","timestamp":1759062516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217307453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":25,"alternative-id":["S0166354217307453"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.012","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spectrum of activity testing for therapeutics against all four dengue virus serotypes in AG129 mouse models: Proof-of-concept studies with the adenosine nucleoside inhibitor NITD-008","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}